Is there any benefit to changing a monoclonal EGFR inhibitor therapy when one had to be stopped for cutaneous toxicity?

The two anti-EGFR monoclonals both have high rates of cutaneous toxicity. It isn't clear that one is better than the other, so switching Is not a good option.  It is better to reduce the dose and treat through with doxycycline and steroids.  Generally the rash will improve within 4-6 weeks.  In the case the patient did not progress and the drug was stopped in the remote past without progression, I would definitely retreat with prophylactic cutaneous care. And of course, warn the patient they will have a bad rash.